risk factor

Higher COVID-19 Risk Tied to 2 MS Therapies, Even With Vaccination

Fully vaccinated multiple sclerosis (MS) patients who are treated with Ocrevus (ocrelizumab) or Gilenya (fingolimod) have a significantly higher risk of COVID-19 infection than those given other immunosuppressive therapies, according to a study in Italy. Called breakthrough infections, these post-vaccination cases of SARS-CoV-2 ā€” the virus that causes…

T. Gondii Parasite May Protect Against Developing MS

Toxoplasmosis, an infection by the parasiteĀ Toxoplasma gondii,Ā has a protective effect against the development of multiple sclerosisĀ (MS), according to a review study. Specifically, people who had been infected with the parasite were 32% less likely to develop MS than those who never had toxoplasmosis. While these findings support T. gondii…